BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 29101459)

  • 1. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.
    Claes KJ; Bammens B; Kuypers DR; Meijers B; Naesens M; Sprangers B; Vanrenterghem Y; Lerut E; de Loor H; Evenepoel P
    Nephrol Dial Transplant; 2014 Oct; 29(10):1965-72. PubMed ID: 24957811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
    Hov GG; Aasarød KI; Sagen E; Åsberg A
    Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
    Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
    Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
    Shafi T; Hostetter TH; Meyer TW; Hwang S; Hai X; Melamed ML; Banerjee T; Coresh J; Powe NR
    Am J Kidney Dis; 2017 Jul; 70(1):48-58. PubMed ID: 28089476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach.
    Oliva-Damaso E; Oliva-Damaso N; Rodriguez-Esparragon F; Payan J; Baamonde-Laborda E; Gonzalez-Cabrera F; Santana-Estupiñan R; Rodriguez-Perez JC
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.
    Zobel EH; von Scholten BJ; Reinhard H; Persson F; Teerlink T; Hansen TW; Parving HH; Jacobsen PK; Rossing P
    Cardiovasc Diabetol; 2017 Jul; 16(1):88. PubMed ID: 28697799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.
    Wang Z; Tang WH; Cho L; Brennan DM; Hazen SL
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1383-91. PubMed ID: 19542023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation of asymmetric and symmetric dimethylarginine: an undercharacterized pathway of metabolism of endogenous methylarginines.
    Rodionov RN; Martens-Lobenhoffer J; Brilloff S; Burdin DV; Jarzebska N; Demyanov AV; Hohenstein B; Weiss N; Bode-Böger SM
    Nephrol Dial Transplant; 2016 Jan; 31(1):57-63. PubMed ID: 26610597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric Dimethylarginine Predicts Long-Term Outcome in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    Vögeli A; Ottiger M; Meier MA; Steuer C; Bernasconi L; Huber A; Christ-Crain M; Henzen C; Hoess C; Thomann R; Zimmerli W; Mueller B; Schuetz P
    Lung; 2017 Dec; 195(6):717-727. PubMed ID: 28852826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
    Siegerink B; Maas R; Vossen CY; Schwedhelm E; Koenig W; Böger R; Rothenbacher D; Brenner H; Breitling LP
    Clin Res Cardiol; 2013 Mar; 102(3):193-202. PubMed ID: 23073705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum reference intervals of homoarginine, ADMA, and SDMA in the study of health in Pomerania.
    Atzler D; Schwedhelm E; Nauck M; Ittermann T; Böger RH; Friedrich N
    Clin Chem Lab Med; 2014 Dec; 52(12):1835-42. PubMed ID: 24945429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction.
    Cavalca V; Veglia F; Squellerio I; De Metrio M; Rubino M; Porro B; Moltrasio M; Tremoli E; Marenzi G
    PLoS One; 2012; 7(11):e48499. PubMed ID: 23185262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The methylarginines NMMA, ADMA, and SDMA are ubiquitous constituents of the main vegetables of human nutrition.
    Servillo L; Giovane A; Cautela D; Castaldo D; Balestrieri ML
    Nitric Oxide; 2013 Apr; 30():43-8. PubMed ID: 23438481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylated arginine derivatives in children and adolescents with chronic kidney disease.
    Brooks ER; Langman CB; Wang S; Price HE; Hodges AL; Darling L; Yang AZ; Smith FA
    Pediatr Nephrol; 2009 Jan; 24(1):129-34. PubMed ID: 18830716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Admission levels of asymmetric and symmetric dimethylarginine predict long-term outcome in patients with community-acquired pneumonia.
    Vögeli A; Ottiger M; Meier MA; Steuer C; Bernasconi L; Kulkarni P; Huber A; Christ-Crain M; Henzen C; Hoess C; Thomann R; Zimmerli W; Mueller B; Schuetz P
    Respir Res; 2017 Jan; 18(1):25. PubMed ID: 28114935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.
    Fleck C; Janz A; Schweitzer F; Karge E; Schwertfeger M; Stein G
    Kidney Int Suppl; 2001 Feb; 78():S14-8. PubMed ID: 11168976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
    Schrauben SJ; Sapa H; Xie D; Zhang X; Anderson AH; Shlipak MG; Hsu CY; Shafi T; Mehta R; Bhat Z; Brown J; Charleston J; Chen J; He J; Ix JH; Rao P; Townsend R; Kimmel PL; Vasan RS; Feldman HI; Seegmiller JC; Brunengraber H; Hostetter TH; Schelling JR;
    Nephrol Dial Transplant; 2023 Nov; 38(12):2809-2815. PubMed ID: 37230949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.
    Schulze F; Carter AM; Schwedhelm E; Ajjan R; Maas R; von Holten RA; Atzler D; Grant PJ; Böger RH
    Atherosclerosis; 2010 Feb; 208(2):518-23. PubMed ID: 19700158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.